MAP2K7 and non-small cell lung carcinoma: In a similar study, Muthu Kumar and colleagues29 introduced another drug repurposing method for NSCLC, and they hypothesized that Nebivolol is an excellent candidate for inhibiting MEK in NSCLC patients.